Skip to main content

Table 1 Baseline characteristics of all patients

From: Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-up

 Ulinastatin group
(n = 142)
Tranexamic acid group
(n = 143)
Placebo group
(n = 141)
p
Baseline demographics
 Male n,(%)63 (44.37%)66 (46.15%)71 (50.35%)0.585
 Age (yrs)49.0 ± 14.348.6 ± 12.750.3 ± 12.40.562
 Weight (kg)61.7 ± 11.761.4 ± 12.061.4 ± 12.70.907
 Body mass index23.1 ± 3.622.9 ± 3.422.8 ± 3.70.686
Diagnosis0.631
 Coronary heart disease, n(%)17 (11.97%)13 (9.09%)21 (14.89%) 
Valvular heart disease, n(%)
 Mitral valve lesion, n(%)70 (49.30%)66 (46.15%)63 (44.68%) 
 Aortic valve lesion, n(%)24 (16.90%)23 (16.08%)19 (13.48%) 
 Combined lesion, n(%)21 (14.79%)19 (13.29%)19 (13.48%) 
Congenital heart disease, n(%)
 Atrial septal defect, n(%)1 (0.70%)4 (2.80%)6 (4.26%) 
 Ventricular septal defect, n(%)4 (2.82%)6 (4.20%)5 (3.55%) 
 Other, n(%)5 (3.52%)12 (8.39%)8 (5.67%) 
Clinical history (%)
 Hypertension31 (21.83%)33 (23.08%037 (26.24%)0.668
 Diabetes5 (3.52%)4 (2.80%)6 (4.26%)0.801
 Stroke7 (4.93%)3 (2.10%)2 (1.42%)0.166
 Chronic pulmonary disease10 (7.04%)19 (13.29%)15 (10.64%)0.221
 Liver dysfunction0 (0%)0 (0%)0 (0%)
 Renal dysfunction0 (0%)1 (0.70%)2 (1.42%)0.361
NYHA class (%)0.610
 I10 (7.04%)18 (12.59%)18 (12.77%) 
 II81 (57.04%)75 (52.45%)78 (55.32%) 
 III41 (28.87%)36 (25.17%)35 (24.82%) 
 IV10 (7.04%)14 (9.79%)10 (7.09%) 
 Euroscore II2.41 ± 1.872.63 ± 1.732.50 ± 1.750.549